Jeena Sikho Lifecare Limited (JSLL) share price
₹417.20 on NSE as of 2026-10-07. -5.45% on the day. market cap ₹5,186 Cr. P/E 21.9. 52-week range ₹417.20 to ₹812.10. Consumer Services.
Jeena Sikho Lifecare Q1 FY27: ₹224 Cr Revenue, 2,400 Ayurvedic Beds, and ₹14 Cr of Other Income
At a glance
Jeena Sikho Lifecare sells Ayurvedic treatment through its own hospitals and clinics, and Ayurvedic medicine under its own brand. Revenue from operations reached ₹224.40 crore in the three months to June 2026. The same quarter a year earlier brought ₹174.29 crore, a rise of 28.8%. Operating profit for the quarter was ₹92.11 crore, up 16.9% on the year. Net profit came in at ₹65.69 crore, an increase of 28.0%. Earnings per share, the profit attached to each share, was ₹5.28 against ₹4.13.
Behind those lines sits a company running 62 Ayurvedic hospitals and 57 clinics across 23 states. It also sells more than 330 lines of Ayurvedic medicine. In an August announcement, the company signed a licence agreement for a wellness centre at a Manali resort. The property has 30 rooms and the licence fee is ₹7.66 crore. A helipad is planned in a later phase, which is an unusual line in a Panchakarma business plan.
Other income for the quarter was ₹14.02 crore, against ₹1.07 crore a year earlier. The CFO stated that roughly ₹7 crore of that was one-off. That figure covered about ₹5 crore of warrant valuation and ₹2.5 crore of capital gains. The CFO indicated normalised other income of ₹4 crore to ₹5 crore.
Management, on the call, asked investors to read the full year rather than the quarters. The company has now reported nine consecutive quarters of them.
Operational beds stood at about 2,400, roughly 100 more than the previous quarter. Reported occupancy was about 59%.
Introduction
Jeena Sikho Lifecare describes itself as one of India's leading Ayurvedic healthcare system providers. The company counts roughly ten years of healthcare operations behind it.
The corporate journey, as the company tells it, runs in tidy stages. It began with an idea, then sales of medicine and products. A first Ayurveda healthcare centre followed in Chandigarh, then a Panchakarma hospital at Derabassi. Panchakarma is a course of Ayurvedic cleansing therapies given over several days. An initial public offering of ₹55.5 crore came next, then fifty operational centres. The company then marks a year of ₹324 crore in revenue.
The listing history has stages of its own. The company listed on the NSE in April 2022. It migrated to the NSE and BSE mainboard in August 2025.
Recent months have kept the company secretary's desk busy. On 15 July 2026 the board accepted the resignation of the Company Secretary and appointed Priya Goyal. The same sitting appointed Ajay Sharma and Sapna Singh as independent directors. It also appointed Dr Ish Sharma and Ankush Kaushal as whole-time directors. That is five appointments and one exit in a single meeting.
On 7 August 2026 the board recommended re-appointing Managing Director Manish Grover and Whole-time Director Bhavna Grover. It also recommended re-appointing Karan Vir Bindra as an independent director. Each term runs five years from 25 August 2026, subject to shareholder approval. That meeting commenced at 4:30 p.m. and concluded at 4:42 p.m. Twelve minutes covered a quarter's results and three five-year terms.
On 10 June 2026 the company commenced operations at a 100-bed hospital in Mathura, Uttar Pradesh. The building runs to roughly 60,000 square feet with eight outpatient departments, where patients are seen without being admitted. On 13 August 2026 it disclosed a proposal for a hospital of more than 40 beds at Bareilly. The company put the timing at November 2026 and the spending at about ₹85 lakh. On 19 June 2026 the board approved the sale of the Derabassi hospital's land and building. M/s VSB Enterprises is the buyer and the price is ₹9.05 crore. The company intends to keep running the hospital from the same premises under a proposed lease.
Business model
The company runs two verticals and presents them as a single loop that feeds itself.
The first is Ayurvedic healthcare services. That covers inpatient treatment at the hospitals, where a patient is admitted to a bed. Outpatient care runs through the clinics and daycare centres, alongside Panchakarma therapies and diet care. The company also organises 72-hour health camps.
The second is Ayurvedic healthcare products, sold under the brand Shuddhi. Manufacturing is done entirely by third parties. The goods reach buyers through the centres, a tele-calling support desk and e-commerce.
In the three months to June 2026, services brought in ₹106 crore against ₹118 crore for products. The medicine cabinet out-earned the hospitals. Gross margin was 91% on services and 86% on products. Gross margin is what is left of sales after the direct cost of delivering them. Both figures sit above 85%. The bulk of the spending appears further down the statement.
The physical footprint is large. There are 62 hospitals, along with 57 clinics and daycare centres. These sit across 23 states and more than 100 cities and towns. Operational beds number about 2,400, with 450 more in the pipeline. Staffing is given as about 601 certified Ayurveda doctors and 959 supporting healthcare personnel. Thirty-one centres are run by franchisees. The franchise partner carries the building and running costs, with doctor payroll the exception. The doctors and the products stay on the company's side of the fence.
Capital cost per bed is stated at ₹3 lakh to ₹4 lakh. The company puts the allopathy equivalent at ₹30 lakh to ₹50 lakh. A 100-bed facility is costed at ₹250 lakh to ₹350 lakh in total. Break-even is put at roughly 35% occupancy. Revenue potential is stated at ₹8,360 per bed per day on a bundled Panchakarma basis.
Quarterly results, balance sheet, cash flow, ratios, shareholding and the filings themselves are on the full page for Jeena Sikho Lifecare Limited.
Companies in the same industry as Jeena Sikho Lifecare Limited
Wellness